Previous Page  29 / 52 Next Page
Information
Show Menu
Previous Page 29 / 52 Next Page
Page Background

FYSIOTERAPEUTEN 5/16

29

monitoring and level achieved. The TIDieR

checklist will help improve the quality of in-

tervention reporting more if it is used not

only by study authors, but also journal edi-

tors, peer reviewers, ethics committees, and

funding agencies. A copy of the checklist is

available at:

http://www.equator-network. org/reporting-guidelines/tidier/

.

In summary, incomplete reporting of

interventions in physiotherapy studies is

an important problem and we endorse the

use of the TIDieR checklist as a potential

solution. The responsibility for improving

intervention reporting extends beyond the

authors of individual trials to journal editors

and others who can mandate the use of the

TIDieR checklist to combat this problem.

Mandating the use of the TIDieR checklist

would guide authors to describe their in-

terventions better and, consequently, help

clinicians to use the interventions and rese-

archers to synthesise and replicate the evi-

dence.

At Fysioterapeuten, the TIDieR state-

ment will be incorporated into manuscript

processing workflow from 01.01.2017. Sub-

mitting authors are encouraged to use the

TIDieR checklist to ensure that any inter-

ventions described in their manuscript are

fully reported. However, submitting authors

will not be required to submit the checklist.

The editor will make an initial decision abo-

ut the suitability of the manuscript for peer

review. For manuscripts that are suitable for

review, the editor will check the manuscript

against the checklist to ensure that all items

are fully reported. Manuscripts that do not

report all relevant aspects of the interventi-

on will be returned to the authors to address

the gaps in reporting before the manuscript

will progress to peer review. Submitting

authors with questions about the checklist

are invited to contact the journal’s editorial

team at

fagredaktor@fysio.no

.

References

1. Herbert R, Jamtvedt G, Birger Hagen K, Mead J. Practical

Evidence-based Physiotherapy. 2nd ed. London: Churchill

Livingstone; 2012.

2. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ,

Jr. Adequacy of published oncology randomized controlled

trials to provide therapeutic details needed for clinical

application. J Natl Cancer Inst 2010;102:702-5.

3. Glasziou P, Meats E, Heneghan C, Shepperd S. What

is missing from descriptions of treatment in trials and

reviews? BMJ 2008;336:1472-4.

4. Hoffmann TC, Erueti C, Glasziou PP. Poor description of

non-pharmacological interventions: analysis of consecu-

tive sample of randomised trials. BMJ 2013;347:f3755.

5. Yamato TP, Maher CG, Saragiotto BT, Hoffmann

TC, Moseley AM. How completely are physiotherapy

interventions described in reports of randomised trials?

Physiotherapy 2016.

6. Research: Increasing value, reducing waste. Lancet

2014;383:1-56.

7. Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ,

Macleod MR, Moher D, et al. Increasing value and reducing

waste in research design, conduct, and analysis. Lancet

2014;383:166-75.

8. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R,

Moher D, et al. Better reporting of interventions: template

for intervention description and replication (TIDieR)

checklist and guide. BMJ 2014;348:g1687.

9. Schulz KF, Altman DG, Moher D, Group C. CONSORT

2010 statement: updated guidelines for reporting parallel

group randomised trials. BMJ 2010;340:c332.

10. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche

PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining

standard protocol items for clinical trials. Ann Intern Med

2013;158:200-7.

Vil du bygge din framtid med oss? Til vår landsdekkende Bedriftshelsetjeneste søker vi bedriftsfysioterapeut Les mer og send søknad på veidekke.no/jobb Har du ytterligere spørsmål? Kontakt gjerne bedriftsfysioterapeut Pål Nordaune, 906 99 464 – pal.nordaune@veidekke.no Bedriftslege Kjell Aage Sørensen, 951 43 779 kjell.sorensen@veidekke.no Søknadsfrist: 27. mai 2016 Veidekke er en av Skandinavias største entreprenører og eiendomsutviklere. Selskapet utfører alle typer bygg- og anleggsoppdrag, vedlikeholder veier og produserer asfalt, pukk og grus. Involvering og lokalkunnskap kjennetegner virksomheten. Omsetningen er 24.5 milliarder kroner (2015), og halvparten av de 7 000 medarbeiderne eier aksjer i selskapet. Veidekke er notert på Oslo Børs, og har siden starten i 1936 alltid gått med overskudd.